MRI Scan and Intra-labyrinthine Schwannoma

INTEREST OF INTRAVENOUS INJECTION OF GADOLINIUM IN EXPLORATION INTRA-LABYRINTHINE SCHWANNOMA IN MRI 3 TESLAS

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03580850

Enrollment

Registered

2018-07-09

Start date

2018-02-02

Completion date

2019-02-28

Last updated

2018-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schwannoma

Keywords

intra labyrinthine schwannoma, schwannoma, magnetic resonance imaging (MRI), gadolinium, T2 weighted gradient echo

Brief summary

Evaluate the interest of gadolinium for the positive and topographic diagnosis of intra-labyrinthine schwannoma, comparing T1 sequence acquired after gadolinium injection to a sequence of fast imaging type employing steady state acquisition (FIESTA-C)

Interventions

OTHERNo intervention in this restrospective study

This study is an obervational study

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Age 18-80 years * Have intra-labyrinthine schwannoma * Have benefited from an MRI with gadolinium injection on the MRI 3T with interpretable sequences of good quality * Subject giving their consent for their participation * Subjects who benefited, between 2009 and 2016, from an MRI of the external auditory canals, with gadolinous product injection and on the 3 Tesla MRI, in which a diagnosis of intra labyrinthine schwannoma was made

Exclusion criteria

\- Refusal to participate in the study

Design outcomes

Primary

Measure	Time frame
Presence or absence of intra labyrinthine vestibular nerve tumor using T2 FIESTA alone	1 hour after the realization of the MRI

Countries

France

Contacts

Primary ContactFrancis VEILLON, MD, PhD

Francis.veillon@chru-strasbourg.fr33 3 88 12 78 65

Backup ContactAïna VENKATASAMY, MD

aina.venkatasamy@chru-strasbourg.fr33 3 88 12 78 65

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026